Absolent Air Care Group And 2 Other Stocks On The Swedish Exchange Possibly Undervalued

The Swedish stock market has recently experienced volatility, influenced by broader economic concerns and global market trends. Amidst this turbulence, certain stocks may present undervalued opportunities for discerning investors. Identifying potentially undervalued stocks often involves looking at companies with strong fundamentals that are temporarily out of favor or overlooked by the market. In the current climate, where economic data has driven uncertainty, such opportunities can be particularly compelling for those seeking value investments.

Top 10 Undervalued Stocks Based On Cash Flows In Sweden

Name	Current Price	Fair Value (Est)	Discount (Est)
Sleep Cycle (OM:SLEEP)	SEK41.20	SEK80.59	48.9%
Scandi Standard (OM:SCST)	SEK81.00	SEK161.97	50%
Nilörngruppen (OM:NIL B)	SEK71.00	SEK138.02	48.6%
Stille (OM:STIL)	SEK236.00	SEK446.00	47.1%
Litium (OM:LITI)	SEK8.50	SEK16.57	48.7%
Dometic Group (OM:DOM)	SEK69.85	SEK133.44	47.7%
Flexion Mobile (OM:FLEXM)	SEK9.24	SEK18.03	48.7%
Humble Group (OM:HUMBLE)	SEK9.255	SEK18.50	50%
Ferronordic (OM:FNM)	SEK78.80	SEK157.28	49.9%
Wästbygg Gruppen (OM:WBGR B)	SEK52.20	SEK99.37	47.5%

Click here to see the full list of 47 stocks from our Undervalued Swedish Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

Absolent Air Care Group (OM:ABSO)

Overview: Absolent Air Care Group AB (publ) designs, develops, sells, installs, and maintains air filtration units and has a market cap of SEK3.74 billion.

Operations: Absolent Air Care Group generates revenue primarily from its Industrial segment (SEK1.14 billion) and Commercial Kitchen segment (SEK281.66 million).

Estimated Discount To Fair Value: 36.7%

Absolent Air Care Group appears undervalued, trading at SEK 330, significantly below its estimated fair value of SEK 520.93. Despite recent executive changes and a slight dip in quarterly net income to SEK 40.35 million from SEK 45.66 million, the company's revenue is forecasted to grow faster than the Swedish market at 10% per year. Additionally, earnings are expected to rise by 18.8% annually with a high projected return on equity of 20.4%.

• According our earnings growth report, there's an indication that Absolent Air Care Group might be ready to expand.
• Click to explore a detailed breakdown of our findings in Absolent Air Care Group's balance sheet health report.

Catella (OM:CAT B)

Overview: Catella AB (publ) is a real estate investment firm with a market cap of SEK2.69 billion.

Operations: Catella AB (publ) generates revenue through three main segments: Corporate Finance (SEK433 million), Investment Management (SEK1.13 billion), and Principal Investments (SEK723 million).

Estimated Discount To Fair Value: 14.5%

Catella AB, trading at SEK 30.5, is undervalued compared to its fair value estimate of SEK 35.65. Despite a recent dividend decrease to SEK 0.90 per share, the company reported improved earnings for Q1 2024 with net income of SEK 26 million versus a net loss last year. Forecasts indicate significant annual earnings growth of nearly 50%, although profit margins have declined and debt coverage by operating cash flow remains weak.

• The growth report we've compiled suggests that Catella's future prospects could be on the up.
• Take a closer look at Catella's balance sheet health here in our report.

Xvivo Perfusion (OM:XVIVO)

Overview: Xvivo Perfusion AB (publ) is a medical technology company that develops and markets machines and perfusion solutions for assessing and maintaining organs in optimal condition pending transplantation, with a market cap of SEK15.53 billion.

Operations: The company's revenue segments are Services (SEK83.39 million), Thoracic (SEK451.49 million), and Abdominal (SEK163.85 million).

Estimated Discount To Fair Value: 40%

Xvivo Perfusion AB, trading at SEK 493, is significantly undervalued compared to its fair value estimate of SEK 822.03. The company reported strong earnings for Q2 2024 with net income rising to SEK 27.19 million from SEK 6.89 million a year ago and sales increasing to SEK 210.35 million from SEK 154.57 million last year. Despite past shareholder dilution, forecasts indicate robust annual revenue growth of 26.7% and earnings growth of nearly 37%.

• Our growth report here indicates Xvivo Perfusion may be poised for an improving outlook.
• Delve into the full analysis health report here for a deeper understanding of Xvivo Perfusion.

Where To Now?

• Click through to start exploring the rest of the 44 Undervalued Swedish Stocks Based On Cash Flows now.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com